Beijing Beilu Pharmaceutical Strategic Asset Allocation Index
Beijing Beilu Pharmaceutical strategic asset allocation index. Beijing Beilu Pharmaceutical (300016) has a Strategic Asset Allocation Index of 45.1% as of June 2023. Strategic assets (PP&E of CN¥853.80 Million plus long-term investments of CN¥-) total CN¥853.80 Million, measured against net assets of CN¥1.89 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check Beijing Beilu Pharmaceutical (300016) tangible net worth to evaluate the tangible quality of the company's equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Beijing Beilu Pharmaceutical (2006–2021)
Strategic asset allocation index of Beijing Beilu Pharmaceutical from 2006 to 2021. This chart shows how Beijing Beilu Pharmaceutical's Strategic Asset Allocation Index has evolved across 16 annual periods from 2006 to 2021. As of June 2023, the index stands at 45.1%, representing strategic assets of CN¥853.80 Million against net assets of CN¥1.89 Billion CNY.
Beijing Beilu Pharmaceutical Strategic Asset Allocation Index by Year (2006–2021)
Beijing Beilu Pharmaceutical strategic asset allocation index by year from 2006 to 2021. The table below presents the year-by-year Strategic Asset Allocation Index for Beijing Beilu Pharmaceutical from 2006 to 2021, covering 16 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see market cap of Beijing Beilu Pharmaceutical.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 38.1% | CN¥793.92 Million | CN¥793.92 Million | CN¥- | CN¥2.08 Billion | ▼ -1.0 pp |
| 2020 | 39.1% | CN¥739.48 Million | CN¥739.48 Million | CN¥- | CN¥1.89 Billion | ▼ -29.8 pp |
| 2019 | 68.9% | CN¥998.95 Million | CN¥353.26 Million | CN¥645.69 Million | CN¥1.45 Billion | ▲ +3.8 pp |
| 2018 | 65.1% | CN¥784.49 Million | CN¥331.94 Million | CN¥452.54 Million | CN¥1.21 Billion | ▲ +11.1 pp |
| 2017 | 54.0% | CN¥577.23 Million | CN¥283.25 Million | CN¥293.98 Million | CN¥1.07 Billion | ▲ +1.0 pp |
| 2016 | 53.0% | CN¥478.05 Million | CN¥255.87 Million | CN¥222.18 Million | CN¥901.69 Million | ▲ +23.2 pp |
| 2015 | 29.8% | CN¥278.27 Million | CN¥238.54 Million | CN¥39.73 Million | CN¥932.63 Million | ▲ +0.3 pp |
| 2014 | 29.5% | CN¥196.70 Million | CN¥196.70 Million | CN¥- | CN¥666.33 Million | ▲ +0.8 pp |
| 2013 | 28.7% | CN¥160.81 Million | CN¥160.81 Million | CN¥- | CN¥559.38 Million | ▲ +1.6 pp |
| 2012 | 27.2% | CN¥142.33 Million | CN¥142.33 Million | CN¥- | CN¥523.96 Million | ▲ +11.5 pp |
| 2011 | 15.7% | CN¥77.00 Million | CN¥77.00 Million | CN¥- | CN¥491.47 Million | ▲ +2.2 pp |
| 2010 | 13.4% | CN¥62.88 Million | CN¥62.88 Million | CN¥- | CN¥467.62 Million | ▲ +4.8 pp |
| 2009 | 8.6% | CN¥37.45 Million | CN¥37.45 Million | CN¥- | CN¥433.71 Million | ▼ -18.5 pp |
| 2008 | 27.1% | CN¥36.16 Million | CN¥36.16 Million | CN¥- | CN¥133.23 Million | ▼ -15.1 pp |
| 2007 | 42.3% | CN¥38.17 Million | CN¥38.17 Million | CN¥- | CN¥90.33 Million | ▼ -15.0 pp |
| 2006 | 57.3% | CN¥40.99 Million | CN¥40.99 Million | CN¥- | CN¥71.59 Million | — |